Relief Will Acquire Rights to Potential Sarcoidosis Therapy RLF-100 in Deal

Relief Will Acquire Rights to Potential Sarcoidosis Therapy RLF-100 in Deal

284554

Relief Will Acquire Rights to Potential Sarcoidosis Therapy RLF-100 in Deal

As part of a new agreement with AdVita Lifescience, Relief Therapeutics will acquire the intellectual rights for the specifications and potential applications of an inhaled formulation of RLF-100 (aviptadil). Relief has been collaborating with NeuroRx to advance the development of RLF-100 to treat patients with severe COVID-19 respiratory complications and other lung disorders, including pulmonary sarcoidosis. RLF-100 is an artificial form of a peptide hormone, called vasoactive intestinal peptide (VIP), that is naturally produced throughout…

You must be logged in to read/download the full post.